Registrieren Sie sich, um Meldungen für Instrumente,
Wirtschaftsevents und Inhalte von Autoren zu erhalten, denen Sie folgen
Kostenlose Registrierung Sie haben bereits ein Benutzerkonto? Anmelden
Kurse
Alle Finanzinstrumente
- Alle Finanzinstrumente
- Indizes
- Aktien
- ETFs
- Fonds
- Rohstoffe
- Währungen
- Krypto
- Anleihen
- Zertifikate
Versuchen Sie es noch einmal mit einem anderen Suchbegriff
Insider-Daten freischalten: Bis zu 50% Rabatt auf InvestingPro JETZT ZUGREIFEN
Fidelity Select Pharmaceuticals Portfolio (FPHAX)
Einem Portfolio hinzufügen/entfernen
Portfolio hinzufügen
29,79
+0,41
+1,40%
- Morningstar Rating:
- Aktiva (gesamt): 1,48B
Fidelity Select Pharmaceuticals Port
29,79
+0,41
+1,40%
- Allgemein
- Chart
- Nachrichten & Analysen
- Technisch
- Forum
FPHAX Übersicht
Auf dieser Seite finden Sie ein ausführliches Fidelity Select Pharmaceuticals Portfolio Profil. Erfahren Sie mehr über das Management, das Gesamtvermögen, die Anlagestrategie und die FPHAX Kontaktinformationen.
Kontaktinformation
Adresse
483 Bay Street
Toronto,ON M5G 2N7
Canada
Toronto,ON M5G 2N7
Canada
Telefon
416-307-5200
Fax
1-800-387-8092
Management
| Name | Titel | Seit | Bis |
|---|---|---|---|
| Karim Suwwan de Felipe | Research Analyst/Portfolio Manager | 2017 | Aktuell |
| Biografie | Karim Suwwan de Felipe is a research analyst and portfolio manager in the Equity division at Fidelity Investments. Fidelity Investments is a leading provider of investment management, retirement planning, portfolio guidance, brokerage, benefits outsourcing, and other financial products and services to institutions, financial intermediaries, and individuals. In this role, Mr. Suwwan de Felipe is responsible for covering and providing recommendations on stocks in the global pharmaceutical sector. Additionally, he manages the Fidelity Select Pharmaceuticals Portfolio. Prior to joining Fidelity in 2010, Mr. Suwwan de Felipe was a senior research associate at Citi Investment Research and Analysis. As a member of the biotechnology research team at Citi, he helped formulate recommendations on large and mid-cap biotechnology equities. Previously, Mr. Suwwan de Felipe conducted molecular biology research at CuraGen Corporation, a biotechnology company in Connecticut, and at Yale University’s Department of Therapeutic Radiology. Mr. Suwwan de Felipe earned his bachelor of science degree in molecular biophysics and biochemistry from Yale University, and his doctorate degree with distinction in cellular, molecular, and biophysical studies from Columbia University’s College of Physicians and Surgeons. | ||
| Asher Anolic | Portfolio Manager | 2013 | 2018 |
| Biografie | Asher Anolic is co-manager of the VIP Growth Portfolio, which he has managed since July 2017. He also manages other funds. Since joining Fidelity Investments in 2008, Mr. Anolic has worked as a research analyst and portfolio manager. Prior to joining Fidelity Investments in 2008, Mr. Anolic worked for Bear Stearns as a research analyst. | ||
| Andrew Oh | Equity Research Analyst | 2006 | 2013 |
| Biografie | Oh joined Fidelity Investments in 2006 as an equity research analyst. Prior to Fidelity, he was director and senior pharmaceuticals analyst for Leernik Swann & Company in New York. From 2001 to 2004, he was senior equity research associate following the U.S. large cap pharmaceuticals sector for JP Morgan Chase in New York. | ||
| Harlan P. Carere | Portfolio Manager | 2005 | 2007 |
| Biografie | Carere is a portfolio manager of Fidelity Investments. He joined Fidelity International Limited in London in 2000 as an equity research analyst following the technology sector. He subsequently served as technology sector leader in the London office. Prior to joining the firm, he was an equity analyst for Berman Capital. | ||
| Ian Gutterman | Portfolio Manager | 2005 | 2005 |
| Biografie | Gutterman is a portfolio manager with Fidelity Investments, his employer since 1999. Prior to joining the firm, he was a treasury analyst with MT Bank from 1995 to 1997. | ||
| Gavin Baker | Sector Leader | 2002 | 2005 |
| Biografie | Baker joined Fidelity in 1999 as an equity research analyst following companies in the cement and building materials industries. He subsequently followed the semiconductor industry. In 2002, Baker began following the pharmaceutical sector, and managed Fidelity Select Pharmaceuticals Portfolio from 2002 to 2005. He then started following large- cap consumer stocks before assuming — in 2006 —the role of diversified analyst working with the large– cap growth group. Baker most recently began serving as sector leader of the telecom and utilities equity research group. | ||
| Yolanda S. Strock | equity analyst/portfolio Manager | 2001 | 2002 |
| Biografie | Yolanda Strock joined Fidelity in 1997 where she is the sector leader of the Health Care Equity Resesarch group. She began managing Fidelity Select Biotechnology Portfolio in February 2000, and assumed her other fund management responsibilities and role of sector leader in June 2000. Yolanda has an MBA in Finance from the Fuqua School of Business at Duke University, a BSc in Marketing from the Wharton School of Business and a BA in economics from the University of Pennsylvania. | ||
Was denken Sie über Fidelity Select Pharmaceuticals Portfolio
Sind Sie sicher, dass Sie diesen Chart löschen möchten?
Löschen Abbrechen
Angehängten Chart durch einen neuen Chart ersetzen?
Ersetzen Abbrechen
Community-Richtlinien
Chart zum Kommentar hinzufügen
Sperre bestätigen
Sind Sie sicher, dass Sie %USER_NAME% sperren möchten?
Dadurch werden Sie und %USER_NAME% nicht mehr in der Lage sein, Beiträge des jeweils anderen auf Investing.com zu sehen.
%USER_NAME% wurde erfolgreich zu Ihrer Sperrliste hinzugefügt.
Da Sie diese Person entsperrt haben, müssen Sie 48 Stunden warten, bevor Sie sie wieder sperren können.
Diesen Kommentar melden
Sagen Sie uns Ihre Meinung zu diesem Kommentar
Kommentar markiert
Vielen Dank!
Ihre Meldung wurde zur Überprüfung an unsere Moderatoren geschickt